MBCOF (Marvel Biosciences) Financial Strength: 5 (As of Apr. 2026) — 25% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences Financial Strength?

Marvel Biosciences MBCOF -10.36% 34 Financial Strength is 5 as of Apr. 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Marvel Biosciences has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Marvel Biosciences's Interest Coverage for the quarter that ended in Apr. 2026 was 2.97. As of today, Marvel Biosciences's Altman Z-Score is 0.00.


Marvel Biosciences  (OTCPK:MBCOF) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Marvel Biosciences has the Financial Strength Rank of 5.


Marvel Biosciences Financial Strength Related Terms


MBCOF vs VRTX, REGN, ALNY: Financial Strength Comparison

For the Biotechnology subindustry, Marvel Biosciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences Financial Strength vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Financial Strength distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Financial Strength falls into.


MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Marvel Biosciences's Interest Expense for the months ended in Apr. 2026 was $-0.03 Mil. Its Operating Income for the months ended in Apr. 2026 was $0.09 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.45 Mil.

Marvel Biosciences's Interest Coverage for the quarter that ended in Apr. 2026 is

Interest Coverage=-1*Operating Income (Q: Apr. 2026 )/Interest Expense (Q: Apr. 2026 )
=-1*0.086/-0.029
=2.97

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Marvel Biosciences's Debt to Revenue Ratio for the quarter that ended in Apr. 2026 is

Debt to Revenue Ratio=Total Debt (Q: Apr. 2026 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.561 + 0.454) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Marvel Biosciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 5 mean?
Marvel Biosciences (MBCOF) has a Financial Strength of 5 as of Apr. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Marvel Biosciences and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Marvel Biosciences' Financial Strength has ranged from 3.00 to 5.00.
Is Marvel Biosciences' Financial Strength too high?
Marvel Biosciences' current Financial Strength of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Financial Strength compare to VRTX and REGN?
Marvel Biosciences' Financial Strength of 5 can be compared against companies in the Biotechnology industry. Historically, Marvel Biosciences' own Financial Strength has ranged from 3.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Marvel Biosciences and its competitors. Marvel Biosciences's current Financial Strength is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Financial Strength of 5. The current Financial Strength is 5, which is 25% above median its 10-year median of 4.00. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Financial Strength is 5 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price